Macro Group Pharmaceuticals (Macro Capital)E (MCRO) Stock Overview
Operates as a cosmeceuticals manufacturing company in Egypt and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
MCRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Macro Group Pharmaceuticals (Macro Capital) S.A.E Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م1.35 |
| 52 Week High | ج.م4.11 |
| 52 Week Low | ج.م0.81 |
| Beta | 0.13 |
| 1 Month Change | -59.70% |
| 3 Month Change | -54.55% |
| 1 Year Change | -44.44% |
| 3 Year Change | -64.38% |
| 5 Year Change | n/a |
| Change since IPO | -70.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| MCRO | EG Personal Products | EG Market | |
|---|---|---|---|
| 7D | 48.7% | 1.4% | -2.1% |
| 1Y | -44.4% | -3.0% | 22.6% |
Return vs Industry: MCRO underperformed the EG Personal Products industry which returned -2.6% over the past year.
Return vs Market: MCRO underperformed the EG Market which returned 23.3% over the past year.
Price Volatility
| MCRO volatility | |
|---|---|
| MCRO Average Weekly Movement | 26.0% |
| Personal Products Industry Average Movement | 5.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in EG Market | 9.7% |
| 10% least volatile stocks in EG Market | 3.0% |
Stable Share Price: MCRO's share price has been volatile over the past 3 months compared to the EG market.
Volatility Over Time: MCRO's weekly volatility has increased from 14% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Hisham Wasfy | www.macro-egy.com |
Macro Group Pharmaceuticals (Macro Capital) S.A.E operates as a cosmeceuticals manufacturing company in Egypt and internationally. It engages in the production of pharmaceutical and cosmetic products, such as skin care, hair care, oral care, female intimate care, anti-scar, antiseptics, and topical muscle relaxants, as well as flavors, colors, and scents. The company also manufactures solid and liquid soap, herbal medicines, products and extracts, nutritional supplements, baby food, and special food products.
Macro Group Pharmaceuticals (Macro Capital) S.A.E Fundamentals Summary
| MCRO fundamental statistics | |
|---|---|
| Market cap | ج.م769.78m |
| Earnings (TTM) | ج.م131.91m |
| Revenue (TTM) | ج.م879.03m |
Is MCRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCRO income statement (TTM) | |
|---|---|
| Revenue | ج.م879.03m |
| Cost of Revenue | ج.م285.16m |
| Gross Profit | ج.م593.86m |
| Other Expenses | ج.م461.95m |
| Earnings | ج.م131.91m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 67.56% |
| Net Profit Margin | 15.01% |
| Debt/Equity Ratio | 144.7% |
How did MCRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 06:44 |
| End of Day Share Price | 2025/11/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Macro Group Pharmaceuticals (Macro Capital) S.A.E is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ahmed Moataz | EFG-Hermes Research |